Related Guidance Notes
GNX 12: Getting your voice heard by big pharma
GNX 11: Using Independent Expert Reports for an IPO
GNX 10: Transactions – Good Practice Part II
GNX 9: Transactions – Good Practice Part I
GNX 8: The Divestment Challenge
GNX 7: PharmaVentures Data Room Structure Guideline
GNX 5: M&A in COVID-19 Environment and Beyond – Keep Your Perspective
GNX 6: Why Licensing and Partnering Activity Should Remain Steady in 2020
GNX 4: Partnering Essentials: Identifying and Engaging with Potential Licensees
GNX 3: Will the latest diagnostic technologies change clinical practice?
GNX 2: Interpreting and Negotiating Deal Terms for a Licensing Agreement
GNX 1: Dancing with the Dragon: Cross-border Transactions between China and the World
GNES 13: The Employer Branding Emergency
GNL 38: Product liability – what is a “defect”?
GNL 33: Patents in the company lifecycle: M&A and joint ventures
GNL 23: IP indemnities in commercial agreements
GNL 19: Pre-clinical, clinical and post-market surveillance
GNL 18: Territorial Licensing
GNL 16: The Execution of Documents – Getting it Right
GNL 9: Licensing Patents – Royalties, Warranties & Indemnities and Termination
GNL 8: Licensing Patents – Exclusivity, Territory, Duration and Improvements
GNL 5: Drafting Commercial Agreements – Endeavours and Entire Agreement Clauses, and Contractual Time Bars
GNL 4: Research, Development and Collaboration Agreements
